MLTX - CIK 0001821586
MoonLake Immunotherapeutics (MLTX) reported net income of -$227.32M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$227.32M | -91.1% |
| FY 2024 | -$118.94M | -230.3% |
| FY 2023 | -$36.01M | +27.9% |
| FY 2022 | -$49.97M | -1000.1% |
| FY 2021 | -$4.54M | - |
MoonLake Immunotherapeutics (MLTX) reported net income of -$227.32M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, MoonLake Immunotherapeutics's net income declined from -$4.54M to -$227.32M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.